Skip to content
Biodatica
Start free

Investigator

Rohit N. Kulkarni

JOSLIN DIABETES CENTER · funded by NIDDK

Companies
5

Resolved onto their grants.

Grants
5

Federal awards on file.

Non-dilutive funding
$4.1M

Summed across those awards.

First award
Feb 15, 1997

Latest Jul 1, 2024.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. RC2

    Epitranscriptomics in human obesity and type 2 diabetes

    $2.0M

    Jul 1, 2024NIDDKJOSLIN DIABETES CENTERNIH RePORTER · 11126869 (opens the source filing in a new tab)

  2. U01

    Using ex vivo, in vivo models and patient mutations to interrogate pancreatic exocrine-endocrine cross talk

    $882k

    Sep 20, 2022NIDDKJOSLIN DIABETES CENTERNIH RePORTER · 11144314 (opens the source filing in a new tab)

  3. R01

    Role of IGF-1 and insulin receptors beta-cell survival

    $704k

    Mar 1, 2004NIDDKJOSLIN DIABETES CENTERNIH RePORTER · 11232330 (opens the source filing in a new tab)

  4. P30

    Pilot and Feasibility Program

    $284k

    Feb 15, 1997NIDDKJOSLIN DIABETES CENTERNIH RePORTER · 11118899 (opens the source filing in a new tab)

  5. P30

    Pilot and Feasibility Program

    $284k

    Feb 15, 1997NIDDKJOSLIN DIABETES CENTERNIH RePORTER · 11364079 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources